Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
National multicentric registry of a cohort of patient with suffering parietal endometriosis, carried out by a multidisciplinary radiosurgery team
Patient who suffering of parietal endometriosis treat by cryoablation or chirurgical will be recorded in national registry. the patient will be follow during 3 years after treatement.
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| creation of a national registry for the removal of nodules by cryoablation or surgery for parietal endometriosis | number of Endometriosis 's patient treat by cryoablation or surgical | at inclusion |
| Measure | Description | Time Frame |
|---|---|---|
| Characterize the epidemiology of parietal endometriosis nodules | average of parietal endometriosis nodules | at 1 month, 6month 1year 2 years and 3 years after treatmeant |
| Characterize the epidemiology of parietal endometriosis nodules |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
patient with endomecriosis at least 18 years of age who will be oer are treate by cryo ablation or surgical treatement
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Léo Razakamanantsoa, Dr | Contact | 0157023567 | Leo.Razakamanantsoa@chicreteil.fr |
| Name | Affiliation | Role |
|---|---|---|
| Léo RAZAKAMAMANTSOA | CHIC | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU bordeaux | Recruiting | Bordeau | France |
Not provided
Not provided
Not provided
Not provided
average of parietal endometriosis nodules
| at inclusion |
| To assess the impact of hormone treatment on parietal endometriosis | number of hormone treatment on parietal endometriosis | at 1 month, 6month 1year 2 years and 3 years after treatmeant |
| Assess the demographic distribution of parietal endometriosis | compare the size of of endometriosis nodules pre- and post-treatment | At inclusion |
| Evaluate pre- and post-treatment imaging characteristics of parietal endometriosis | compare the size of of endometriosis nodules pre- and post-treatment | through study completion average 3 years |
| Evaluate the aesthetic impact of the treatments | number of complication | at 1 month after treatmeant |
| Assess the complication rate between the two groups | number of complication between the two groups | at 1 month, 6month 1year 2 years and 3 years after treatmeant |
| Assess the Severity of Complications according to Society (SIR) of Interventional Radiology or Cardiovascular and Interventional Radiological Society of Europe ( CIRSE) for Radiologists | average of Complications according to SIR or CIRSE for Radiologists | at inclusion |
| Assess the Severity of Complications according to Clavien Dindo for the surgeon | average of Complications according to Clavien Dindo for the surgeon | at inclusion |
| Assess the recidivism rate at 3 years | number of recidivism at 3 years | at 3 years |
| Assess the quality of life between the two groups with PGIC-7 questionnaire | average Patient Global Impression of Change PGIC-7 score : PGIC is a 7 point scale depicting a patient's rating of overall improvement. Patients rate their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse." | at inclusion,1 month, 6 months 1year 2 years and 3 years after treatmeant |
| Assess the quality of life between the two groups with asses EHP-5 questionnaire | average EHP-5 score ( Endometriosis Health Profil -5). Each item is rated on a four-point scale (never = 0, rarely = 1, sometimes = 2, often = 3, always = 4 and not relevant if not applicable). Scores on the EHP-5 core and modular questionnaire then are transformed on a scale of 0 (indicating best possible health status) to 100 (indicating worst possible health status) | at inclusion,1 month, 6 months 1year 2 years and 3 years after treatmeant |
| Assess the quality of life between the two groups with asses VAS questionnaire | average VAS score ( Analog Visual Scale) : VAS measures pain intensity on a scale from 0 to 10 (or sometimes from 0 to 100) | at inclusion,1 month, 6 months 1year 2 years and 3 years after treatmeant |
| Evaluate signal and morphology changes on imaging MRI of parietal endometriosis nodules after cryoablation treatment | average of size of endometriosis nodules after cryoablation treatment | at inclusion,1 month, 6 months 1year 2 years and 3 years after treatmeant |
| Evaluate signal and morphology changes on ultrasound imaging of parietal endometriosis nodules after cryoablation treatment | average of size endometriosis nodules after cryoablation treatment | at inclusion,1 month, 6 months 1year 2 years and 3 years after treatmeant |
| Clinique Tivoli | Recruiting | Bordeaux | France |
|
| CHU Clermont Ferrand | Recruiting | Clermont-Ferrand | France |
|
| CHI Creteil | Recruiting | Créteil | France |
|
| Lyon Hôpital La Croix Rousse | Recruiting | Lyon | France |
|
| Lyon Hôpital Sud | Recruiting | Lyon | France |
|
| Lyon Louis Pradel | Active, not recruiting | Lyon | France |
| APHM-Hôpital Nord | Active, not recruiting | Marseille | France |
| APHP-Hôpital la Conception La Timone | Recruiting | Marseille | France |
|
| CHU Montpellier | Recruiting | Montpellier | France |
|
| CHU Nime | Recruiting | Nîmes | France |
|
| AP-HP - Tenon | Recruiting | Paris | France |
|
| AP-HP Hôpital Européen Georges Pompidou | Recruiting | Paris | France |
|
| APHP Cochin-Port Royal | Recruiting | Paris | France |
|
| APHP-La Pitié | Recruiting | Paris | France |
|
| CHU Strasbourg | Enrolling by invitation | Strasbourg | France |
| CHU Toulouse | Active, not recruiting | Toulouse | France |
| CH Valencienne | Recruiting | Valenciennes | France |
|
| ID | Term |
|---|---|
| D004715 | Endometriosis |
| ID | Term |
|---|---|
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
Not provided
Not provided